- CEO
- Xu Heng Deng
- Full Time Employees
- 3,126
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Korgas China
- IPO Date
- Dec 27, 2022
- Business
- Yili Chuanning Biotechnology Co., Ltd. is a China-based biomanufacturing enterprise engaged in the research, development, production, and commercialization of biological fermentation products, pharmaceutical intermediates, and synthetic biology materials. Founded in 2010 and headquartered in Yining, Xinjiang Uygur Autonomous Region, China, the company operates as a key subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd. and trades on the Shenzhen Stock Exchange.
The company offers a diversified biomanufacturing portfolio structured around industrial-scale microbial fermentation and synthetic biology platforms. Its core products and services comprise: antibiotic intermediates, including erythromycin thiocyanate, 6-aminopenicillanic acid (6-APA), penicillin G potassium industrial salt, 7-aminocephalosporanic acid (7-ACA), and deacetyl-7-aminocephalosporanic acid (D-7-ACA); cosmetic and high-end personal care active ingredients, including bio-synthesized alpha-bisabolol, ergothioneine, ectoine, squalane, phytosphingosine, and ceramides; nutritional, healthcare, and animal feed ingredients, including 5-hydroxytryptophan (5-HTP), inositol, and coenzyme Q10; bio-based materials, including polyhydroxyalkanoates (PHA) biodegradable polymers; biological agricultural formulations and biopesticide raw materials; and technical bioprocess services, including chassis cell engineering, automated high-throughput strain screening, and contract biomanufacturing.
Yili Chuanning Biotechnology operates large-scale manufacturing facilities in Xinjiang to leverage local agricultural feedstocks and competitive energy resources, complemented by an advanced synthetic biology innovation center operated by its subsidiary, Shanghai Recom Biotechnology R&D Co., Ltd., in Shanghai. The company serves pharmaceutical manufacturers, personal care brands, and agricultural enterprises across China as well as export destinations in Asia, Europe, and the Americas.
In recent strategic developments, the company has advanced its dual-wheel growth strategy combining traditional fermentation with synthetic biology, commissioning its dedicated synthetic biology industrial production facility in Gongliu, Xinjiang, to commercialize high-margin specialty ingredients such as bisabolol and ergothioneine. The company entered into a strategic partnership with Beijing PhaBuilder Biotechnology Co., Ltd. to establish a joint venture, Xinjiang Weining Biotechnology Co., Ltd., dedicated to scaling the production of medical-grade and industrial polyhydroxyalkanoates (PHA). Furthermore, the company partnered with Shanghai Jincheng Technology to deploy artificial intelligence algorithms and machine learning models for real-time fermentation control and enzyme engineering, while expanding international market access through a commercial cooperation agreement with South Korea-based ACTIVON to distribute functional cosmetic active ingredients globally.